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CLUSION: Secondary prophylactic treatment with tacrolimus
0.1% ointment is more effective, leads to cost savings and higher
QoL in comparison to standard tacrolimus 0.1% ointment use,
especially in patients with severe AD.
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PSOBEST. EFFECTIVENESS AND SAFETY OF LONG-TERM
SYSTEMIC PSORIASIS-THERAPY: PATIENT REGISTRY OF
HEALTH SERVICES IN GERMANY
Rustenbach SJ, Schäfer IA, Radke M,Augustin M
University Clinics of Hamburg, Hamburg, Germany
OBJECTIVES: Treatment of severe Psoriasis (Pso) and Psoriasis-
Arthritis (PsA) is largely conﬁned to conventional systemic-
therapy in Germany, though authorisation of biologics greatly
enhanced the therapy-spectrum. While short- and middle-term
efﬁcacy of systemic-therapy has been shown in many clinical
studies (and is incorporated in international guidelines), knowl-
edge about long-term outcome, optimal treatment and real world
effectiveness is still missing. PsoBEST, the German registry of
systemic treatments in moderate to severe Pso and PsA starts in
2007 and will document the long-term course of patients ﬁrst
entrained to a biologic or conventional systemic. Objectives are
the observation and analysis of following outcomes of systemic
antipsoriatrics authorisized: Effectiveness of real world, long-
term, combined/alternating treatments and under comorbidity
conditions. Patient-deﬁned beneﬁts, maintenance dosages, pre-
diction of response and safety. METHODS: A nationwide sample
of initially 250 (long-term approx. 500) dermatologic practices/
hospital ambulances with expertise in systemic and biologic
treatment will enrol patients consecutively. Patients will remain
in the registry for 5 years, regardless of subsequential therapy.
Study phase 1 will cover n = 3500 patients in 7 cohorts, for
which recruitment will be continued up to n = 500. Documenta-
tion will comprise patient/treatment characteristics, clinical
parameters, patient-deﬁned beneﬁt (PBI), quality of life and
adverse events. Standardized questionnaires are provided to
patients and practitioners 12 times at the dermatologic centres
and 9 times postal at interim intervals (patients residence).
Requirements of Volume 9a (EMEA) and of relevant interna-
tional guidelines on outcomes research in observational studies
are incorporated. PsoBest is aligned to planned EU-registries
(GB, N, S, E and F), relevant endpoints are comparable. Scientiﬁc
quality is assured by an interdisciplinary advisory board, AWMF,
EMEA and BfArM involvement/consultation and certiﬁcation by
DIN ISO 9001:2000. Descriptive reports will be generated regu-
larly, hypotheses will be tested e.g. by MAN(C) OVA, multiple/
logistic/ survival regression and multilevel modelling.
Comparisons between cohorts will be achieved by propensity
score matching.
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COST COMPARISON BETWEENTWO ANTI-TUMOR
NECROSIS FACTOR (ANTI-TNF)THERAPIES IN PATIENTS
WITH PSORIASIS USING AVERAGE SALES PRICE
Tang B, Rahman MI,Thompson HC, Hilliard R, Naim A, Dabbous O
Centocor, Inc, Horsham, PA, USA
OBJECTIVES: To compare annual costs of anti-TNF therapies in
patients with psoriasis (PsO). METHODS: A decision-model was
created using TreeAge software, with clinical trial data and
average sales price (ASP) +6% (2Q 2007) for drug costs. Two
treatment strategies were compared: etanercept ﬁrst then switch-
ing to inﬂiximab and inﬂiximab ﬁrst then switching to etaner-
cept. The model assumed patients who failed to achieve Psoriasis
Area and Severity Index (PASI)-50 would switch to the other
biologic after 24 weeks. The efﬁcacy rates after switching were
assumed to be the same as the ﬁrst-line treatment. A sensitivity
analysis reducing the efﬁcacy rates after switching by 10%-30%
was conducted. The cost of adverse events was not included in
the model. Infusion fees ($237.92/infusion–2Q 2007) were
included for inﬂiximab. RESULTS: With inﬂiximab, 90% of
patients achieved PASI-50 at week-24 and continued receiving
inﬂiximab. Patients (10%) who failed to achieve PASI-50
were switched to etanercept. With etanercept, 77% of patients
achieved PASI-50 at week-24 and continued etanercept
treatment. Patients (23%) who failed to achieve PASI-50 were
switched to inﬂiximab. The etanercept-ﬁrst strategy costs
$22,113 annually and results in an overall efﬁcacy rate of 78.5%
and a cost-efﬁcacy (CE) of $28,171. The inﬂiximab-ﬁrst strategy
costs $23,544 annually and results in an 89.4% efﬁcacy rate and
a CE of $26,351. Compared with etanercept, the inﬂiximab-ﬁrst
strategy costs $1820 less per PASI-50 response. The incremental
CE ratio per PASI-50 was $13,190. The sensitivity analysis indi-
cated that the results are robust and in the same direction as the
original assumption. CONCLUSION: This decision model dem-
onstrates that an inﬂiximab-ﬁrst strategy is more cost-effective
than an etanercept-ﬁrst strategy in the treatment of psoriasis.
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Further studies using real-world data to explore the impact of
anti-TNF therapy on patients’ clinical, economic, and humanistic
outcomes are recommended.
PSK5
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OBJECTIVES: Human Genital warts (GW) are common and
increasing in sexually active people. Ninety percent of GW are
due to Human Papillomavirus (HPV) types 6 and 11. Current
treatments can be long, painful, sometimes fail, and relapses are
frequent. The objective of this study was to assess treatment
patterns and costs associated with the treatment of GW in Italy.
Such estimation is important to assess the cost-effectiveness of
Gardasil®, the quadrivalent HPV vaccine (types 6, 11, 16 &
18). METHODS: A national retrospective observational study
was designed to involve 40 investigators in public gynaecologi-
cal, dermatological, and sexually transmitted disease centres,
enrolling 360 patients aged 14–64 years, with newly diagnosed
or recurrent GW. Investigators documented medical resource
utilisation and absence from work for the treatment of GW and
related complications in 2005 (physician visits, diagnostic tests,
medications, ofﬁce-based treatments, hospitalisations, days off
work). Annual direct medical costs per patient were estimated
along with productivity losses from the societal perspective.
RESULTS: A total of 28 investigators enrolled 341 patients
(189 men and 152 women); 8 patients were admitted directly
to day-hospital and 333 (97.7%) had at least one investigator
visit (on average 3.4 visits); 267 outpatient cases (80.2%)
underwent at least one ofﬁce-based procedure. 124 patients
(36.4%) were prescribed a self-applied therapy. 39 cases
(11.4%) were admitted to day-hospital. 47 patients (13.8%)
reported a medical complication related to GW treatment.
Mean annual direct medical costs per patient were €242 for
men and €332 for women. Mean costs per patient including
productivity losses were €325 and €464 for men and women,
respectively. CONCLUSION: This study is the ﬁrst to identify
therapeutic patterns and costs of GW in Italy. Treatment costs
are in line with recent European estimates, whereas a wider use
of ofﬁce-based procedures instead of self-applied therapies was
found.
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CARE COSTS AND RESOURCE UTILIZATION AMONG
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OBJECTIVES: To assess the impact of psoriasis (PsO) on health
care costs and resource utilization among Medicaid beneﬁciaries.
METHODS: A retrospective analysis, using samples of the Med-
icaid Statistical Information System (MSIS) patients (pts) with a
diagnosis (dx) of PsO (ICD-9 code 696.1) from January 1, 2003
through December 31, 2005 was conducted. The comparison
group consisted of Medicaid patient population minus individu-
als with any immunological diseases. Health care resource utili-
zation and costs were calculated. Multivariable analysis was
conduct to test the impact of PsO on health care costs and
utilization adjusting for age, gender, and comorbidities (Deyo-
Charlson comorbidity index score). RESULTS: The cohort con-
sisted of 8,551,343 pts, of which 6778 had a PsO dx. 60.4% of
the pts were female and the mean age was 38 yrs. PsO pts had a
higher rate of comorbidities than the controls (1.5 vs 0.41,
p < 0.0001). Mean annual total health care costs for PsO pts
were $5237, compared with $1323 (p < 0.0001) for controls.
Inpatient, outpatient, and physician costs constituted over 45%
of the total health care costs in the PsO cohort. Total health care
visits were over 3.5 times higher for the PsO cohort compared to
the controls (27.4 vs 7.6, p < 0.0001). Physician and outpatient
visits constituted 82% of the resource utilization in the PsO
cohort. After adjustment in the regression analysis, total health
care costs were 63% more for pts with PsO than the controls and
total health care visits were 42% more for pts with PsO than the
control cohort. CONCLUSION: PsO pts have signiﬁcant health
care costs and resource consumption at a much higher rate than
non-PsO pts among Medicaid recipients. New therapies may
have the potential to decrease the disease burden for pts with
PsO. Additional studies are needed to assess differences in quality
of life and health outcomes related to speciﬁc treatments for pts
with PsO.
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Currie CJ1, Conway P2
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OBJECTIVES: Severe psoriasis can result in considerable
decrease in quality of life, and this is likely to be reﬂected in an
increase in costs. The purpose of this study was characterise
resource use in those with psoriasis and determine if there
exists an association between psoriasis severity and hospital
resource use. METHODS: Psoriasis patients were identiﬁed at
hospital clinic, and sent the HODaR survey which also
included the Dermatology Life Quality Index (DLQI). The
DLQI was used to classify severity. Data concerning each
patients’ hospital admissions and outpatient attendances were
identiﬁed from the patient records, other resources such as GP
attendances were self reported by survey. This data was col-
lected over a number of years and an average yearly rate com-
puted. RESULTS: There were 94 respondents to the survey. The
mean time since diagnosis was 15.6 years and 50% were male.
Treatment was reported as follows: topical cream 70.2%, aci-
tretin 14.9%, no reported treatment 10.6%, methotrexate
2.1%, cyclosporine 1.1 and PUVA 1.1%. Retinoid treated
patients were more likely to be male and topical cream treated
subjects were more likely to be female. The mean number of
GP consultations in the previous year was 2.79 per subject,
hospital Admissions 2.22, and outpatients attendances 4.70.
Resource use varied by disease severity. By DLQI score (<3,
3 < 6, 6 < 10, and 10, units respectively), subjects reported
the following mean number of GP consultations in the previous
year: 13, 20, 15, and 24, respectively (p < 0.01 [test for trend]).
For outpatient attendances: 15, 16, 8, and 19, respectively
(p < 0.05). For bed occupancy in the previous year: 19.8, 21.7,
17.5, and 58.7 days, respectively (p < 0.01). CONCLUSION:
Patients with psoriasis managed in UK hospitals represent a
considerable ﬁnancial burden, and this burden increases with
increasing disease severity. Measured should be taken to reduce
the severity of psoriasis.
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